Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Oscotec Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

James Kim

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	12.6%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?

Aug 07

Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?

Apr 26

Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?

Feb 23

If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% Returns

Jan 19

Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?

Dec 15

CEO

James Kim (64 yo)

no data

Görev süresi

Mr. Jeung-Keun Kim serves as the Chief Executive Officer at Oscotec Inc. Mr. Kim served as the Head Professor of Biochemistry Classroom of Dental College of Dankook University and Visiting Researcher of De...

Oscotec Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Less than half of directors are independent

Oscotec Inc., Annual General Meeting, Mar 25, 2021

Recent updates

New major risk - Financial data availability

Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?

Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?

Full year 2023 earnings released: ₩635 loss per share (vs ₩763 loss in FY 2022)

Now 23% undervalued

Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's Disease

Now 20% undervalued after recent price drop

Now 25% undervalued after recent price drop

Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2020 earnings released: ₩155 loss per share (vs ₩801 loss in FY 2019)

Oscotec Inc. and Beactica Therapeutics AB Announces License and Collaboration Agreement to Develop New Cancer Drug

Oscotec Inc., Annual General Meeting, Mar 25, 2021

Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?

New 90-day low: ₩36,100

New 90-day low: ₩40,350

If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% Returns

Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?

New 90-day high: ₩69,500

New 90-day high: ₩51,400

New 90-day high: ₩49,700

New 90-day high: ₩44,250

New 90-day high - ₩33,150

CEO

Görev süresi